RAF1 anticorps (AA 641-645)

N° du produit ABIN871697

Détail du produit anti-RAF1 anticorps

Antigène: RAF1 (V-Raf-1 Murine Leukemia Viral Oncogene Homolog 1 (RAF1))

Épitope: AA 641-645

Reactivité: Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp RAF1 est non-conjugé

Application: Western Blotting (WB)

Specificité: The antibody detects endogenous level of total Raf-1 protein.

Purification: Affinity purified

Immunogène: Peptide sequence around AA 641-645 (T-S-P-R-L ) derived from Rat Raf-1. Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates.

Information d'application

Indications d'application: Western blotting: 1:500-1:1000

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: Phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C/-20 °C

Stockage commentaire: Store at -20 °C for long term preservation (recommended). Store at 4 °C for short term use.

Détails sur RAF1

Antigène: RAF1 (V-Raf-1 Murine Leukemia Viral Oncogene Homolog 1 (RAF1))

Autre désignation: Raf-1 (RAF1 Produits)

Synonymes: anticorps CRAF, anticorps NS5, anticorps Raf-1, anticorps c-Raf, anticorps c-raf, anticorps craf, anticorps raf1, anticorps RAF1, anticorps 6430402F14Rik, anticorps AA990557, anticorps BB129353, anticorps Craf1, anticorps D830050J10Rik, anticorps v-Raf, anticorps raf, anticorps cRaf, anticorps Raf-1 proto-oncogene, serine/threonine kinase, anticorps Raf-1 proto-oncogene, serine/threonine kinase a, anticorps v-raf-leukemia viral oncogene 1, anticorps Raf-1 proto-oncogene, serine/threonine kinase S homeolog, anticorps RAF1, anticorps Raf1, anticorps raf1a, anticorps raf1, anticorps raf1.S

Sujet: A-Raf, B-Raf and c-Raf (Raf-1) are the main effectors recruited by GTP-bound Ras to activate the MEK-MAP kinase pathway (1). Activation of c-Raf is the best understood and involves phosphorylation at multiple activating sites including Ser338, Tyr341, Thr491, Ser494, Ser497 and Ser499 (2). p21-activated protein kinase (PAK) has been shown to phosphorylate c-Raf at Ser338 and the Src family phosphorylates Tyr341 to induce c-Raf activity (3,4). Ser338 of c-Raf corresponds to similar sites in A-Raf (Ser299) and B-Raf (Ser445), although this site is constitutively phosphorylated in B-Raf (5). Inhibitory 14-3-3 binding sites on c-Raf (Ser259 and Ser621) can be phosphorylated by Akt and AMPK, respectively (6,7). While A-Raf, B-Raf and c-Raf are similar in sequence and function, differential regulation has been observed (8). Of particular interest, B-Raf contains three consensus Akt phosphorylation sites (Ser364, Ser428 and Thr439) and lacks a site equivalent to Tyr341 of c-Raf (8,9). The B-Raf mutation V600E results in elevated kinase activity and is commonly found in malignant melanoma (10). Six residues of c-Raf (Ser29, Ser43, Ser289, Ser296, Ser301 and Ser642) become hyperphosphorylated in a manner consistent with c-Raf inactivation. The hyperphosphorylation of these six sites is dependent on downstream MEK signaling and renders c-Raf unresponsive to Avruch,

Poids moléculaire: 74 kDa

ID gène: 24703

NCBI Accession: NP_036771

UniProt: P11345

Pathways: Signalisation MAPK, Signalisation RTK, Fc-epsilon Receptor Signaling Pathway, Neurotrophin Signaling Pathway, cAMP Metabolic Process, Stem Cell Maintenance, Hepatitis C, Autophagy, Signaling of Hepatocyte Growth Factor Receptor, VEGF Signaling, BCR Signaling